TİGEN, M. K. Et Al. 2017. Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction. 33. Uluslararası Katılımlı Kardiyoloji Kongresi , (Antalya, Turkey), 23.

TİGEN, M. K., özdil, h., ÇİNÇİN, A. A., KANAR, B. G., gürel, e., SÜNBÜL, M., ... KOL, A.(2017). Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction . 33. Uluslararası Katılımlı Kardiyoloji Kongresi (pp.23). Antalya, Turkey

TİGEN, MUSTAFA Et Al. "Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction," 33. Uluslararası Katılımlı Kardiyoloji Kongresi, Antalya, Turkey, 2017

TİGEN, MUSTAFA K. Et Al. "Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction." 33. Uluslararası Katılımlı Kardiyoloji Kongresi , Antalya, Turkey, pp.23, 2017

TİGEN, M. K. Et Al. (2017) . "Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction." 33. Uluslararası Katılımlı Kardiyoloji Kongresi , Antalya, Turkey, p.23.

@conferencepaper{conferencepaper, author={MUSTAFA KÜRŞAT TİGEN Et Al. }, title={Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction}, congress name={33. Uluslararası Katılımlı Kardiyoloji Kongresi}, city={Antalya}, country={Turkey}, year={2017}, pages={23} }